With Angus Chen, Robert Colletti, Sam Desai, Porter Fleming, Edgar Haug, Jason Kanter, Laura Krawczyk, Richard Kurz, Damon Lewis, Jason Lief, Erika Selli, David Zwally
In the en banc rehearing, the Court considered whether The Medicines Company's use of third-party services to manufacture the patented products triggered the on-sale bar of 35 U.S.C. § 102(b).